Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430169 | 0.93 | CYP19A1 (0.44) | CYP19A1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL757076 | 0.80 | CYP19A1 (0.44) | IDO1TDO2CYP19A1MEN1ALDH1A1 | |
| SCHEMBL7428103 | 0.80 | POLB (0.48) | CYP19A1LMNA | |
| SCHEMBL28825733 | 0.78 | CYP19A1 (0.35) | CYP19A1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL8678280 | 0.77 | CYP19A1 (0.47) | CYP19A1TSHRCNR2MITFLMNA | |
| SCHEMBL29148239 | 0.76 | IDO1 (0.42) | IDO1TDO2CYP19A1AOC3ALDH1A1 | |
| SCHEMBL7279214 | 0.75 | SLC6A2 (0.46) | CYP19A1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL1515185 | 0.75 | AOC3 (0.52) | IDO1TDO2AOC3MEN1KMT2A | |
| SCHEMBL94275 | 0.75 | HTR2A (0.52) | TSHRLMNA | |
| SCHEMBL3539449 | 0.74 | HTR2A (0.59) | IDO1TDO2CYP19A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626043-B1 | Heterocyclic thioesters | MGI GP INC (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1083873-B1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | MGI GP INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1626043-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | GPI NIL HOLDINGS, INC. | 2005-03-17 | — | — | US | claimed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| US-6384056-B1 | COGNITION ACTIVATORS AND NERVE AND VISION DISORDERS | GPI NIL HOLDINGS, INC. | 2002-05-07 | — | — | US | claimed |
| US-20020016341-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | GPI NIL HOLDINGS, INC. | 2002-02-07 | — | — | US | claimed |
| US-6274602-B1 | ADMINISTERING COMPOSTITIONS SUCH AS 3,3-DIMETHYL-1-((2S)-2-(5-(3-PYRIDYL) PENTANOYL)-1-PYRROLIDINE)-1, 2-PENTANEDIONE TO TREAT ALOPECIA OR PROMOTING HAIR GROWTH IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | claimed |
| US-5990131-A | OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY | GPI NIL HOLDINGS INC. (US) | 1999-11-23 | — | — | US | claimed |
| EP-0448765-B1 | Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity | HEUMANN PHARMA GMBH & CO (DE) | 1994-08-17 | — | — | EP | claimed |
| EP-0448765-A1 | Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity | HEUMANN PHARMA GMBH & CO (DE) | 1991-10-02 | — | — | EP | claimed |
| EP-2780326-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | Vivolux Ab (SE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013058691-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | VIVOLUX AB (SE) | 2013-04-25 | — | — | WO | disclosed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5990131-A | OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY | GPI NIL HOLDINGS INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0448765-B1 | Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity | HEUMANN PHARMA GMBH & CO (DE) | 1994-08-17 | — | — | EP | disclosed |
| EP-0448765-A1 | Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity | HEUMANN PHARMA GMBH & CO (DE) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016341-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | ACOT7, HSD17B7, ZDHHC7 | IDO1 1310/4885TDO2 682/4885CYP19A1 23/4885 |
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | ACOT7, HSD17B7, ZDHHC7 | IDO1 1310/4885TDO2 682/4885CYP19A1 23/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | IDO1 3242/4885TDO2 4317/4885CYP19A1 355/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | IDO1 3282/4885TDO2 4439/4885CYP19A1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.